Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A2 in the aorta of hypercholesterolaemic atherosclerotic rabbits

Journal of International Medical Research

Volumn 37, Issue 4, 2009, Pages 1029-1037

  Qiao, Z ^a   Ren, J ^a   Chen, Hong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Atherosclerosis; Atherosclerotic plaque; Lipoprotein associated phospholipase A2; Simvastatin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER; ANIMAL; ATHEROGENIC DIET; CHOLESTEROL INTAKE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL, DIETARY; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; FEMALE; HYPERCHOLESTEROLEMIA; RABBITS; SIMVASTATIN;

EID: 70350495155     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700407     Document Type: Article

References (20)

1. Bilheimer DW, Grundy SM, Brown MS, et al: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983; 80: 4124-4128.
2. Vaughan CJ, Gotto AM, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
3. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719. (Pubitemid 34219772)
4. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
5. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987.
6. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-842.
7. Levy JH: Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis. N Engl J Med 2008; 358: 1515.
8. Persson M, Nilsson JA, Nelson JJ, et al: The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007; 190: 388-396. (Pubitemid 46074030)
9. Zhang B, Fan P, Shimoji E, et al: Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis 2006; 186: 291-301.
10. Demacker PN, Hijmans AG, Brenninkmeijer BJ, et al: Five methods for determining low-density lipoprotein cholesterol compared. Clin Chem 1984; 30: 1797-1800.
11. Liu SX, Hou FF, Guo ZJ, et al: Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1156-1162.
12. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
13. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19: 2909-2917.
14. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-487.
15. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85: 2805-2809. (Pubitemid 18111684)
16. 2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007; 115: 2715-2721.
17. 2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523-2529.
18. 2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008; 39: 1448-1455.
19. 2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931.
20. Shiomi M, Yamada S, Ito T: Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. Atherosclerosis 2005; 178: 287-294. (Pubitemid 40193442)